Shanghai Pharmaceuticals Holding (601607.SH) intends to list and transfer 30% of its stake in Chinese-American Sigmaceutical.

Shanghai Pharmaceuticals Holding (601607.SH) announced that the company plans to transfer 30% of its equity in its jointly-owned subsidiary, China-United States Shanghai Sino-US Pharmaceuticals Co., Ltd. (referred to as "China-United States Sino-US") through a public listing on the property exchange. The listing transfer price will not be less than 1.023 billion yuan. After completion of this transaction, the company will no longer hold any equity in China-United States Sino-US. This transaction will not have a significant impact on the company's normal operations and financial condition, and is beneficial for maintaining state-owned assets, maximizing asset value, and aligning with the interests of the company and all shareholders.